Imutex

About:

Imutex, a startup with a Phase IIa-ready universal flu vaccine.

Top Investors: hVIVO

Description:

Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hVIVO plc to accelerate the development of a Broad-Spectrum Influenza Vaccine (BIV) and a Zika Vaccine. The development of BIV and Zika vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.

Total Funding Amount:

14M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2016-01-01

Founders:

Number of Employees:

1-10

Last Funding Date:

2016-04-28

IPO Status:

Private

Industries: